The latest financial statement is for the year ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Net (loss) income | -397,907 | -356,734 | 4,231,206 | -1,115,463 |
| Non-cash acquired in-process research and development | - | 0 | 0 | 87,749 |
| Share-based compensation | 346,165 | 289,029 | 199,627 | 217,781 |
| Change in fair value of investments | 105,046 | 55,186 | -47,973 | -20,815 |
| Gain on sale of investment | - | - | - | 0 |
| Change in fair value of debt and liability instruments | -47,704 | 113,078 | -78,943 | -78,001 |
| Gain on sale of subsidiary interests | 0 | 376,506 | - | - |
| Gain on deconsolidation of subsidiaries | 11,027 | 3,108 | 32,772 | 29,276 |
| Gain on sale of telavant net assets | 0 | 110,387 | - | - |
| Impairment loss on operating lease right-of-use assets | 15,594 | - | - | - |
| Gain on termination of sumitomo options | - | - | - | 0 |
| Gain on sale of telavant net assets | - | - | 5,348,410 | - |
| Accretion of discount and amortization of premium on available-for-sale marketable securities, net | 22,992 | - | - | - |
| Gain on recovery of contingent consideration | - | 0 | 0 | 114,561 |
| Accretion of discount and amortization of premium on held-to-maturity marketable securities, net | 13,520 | - | - | - |
| Accretion of discount and amortization of premium on marketable securities, net | - | 69,959 | - | - |
| Realized gain from sales of marketable securities | 976 | - | - | - |
| Loss on extinguishment of debt | 0 | -8,848 | - | - |
| Depreciation and amortization | 3,348 | 14,071 | 22,036 | 18,857 |
| Non-cash lease expense | 8,276 | 6,843 | 6,845 | 7,565 |
| Other | -1,828 | -3,762 | -10,249 | 21,206 |
| Other current assets | -11,459 | 25,070 | 81,478 | 31,670 |
| Other assets | 7,416 | 8,758 | -16,488 | - |
| Litigation settlement receivable | 770,235 | - | - | - |
| Accounts payable | 3,418 | -18,168 | 22,684 | 4,359 |
| Accrued expenses | 59,326 | -10,070 | 40,150 | 38,956 |
| Deferred consideration liability | - | - | - | 0 |
| Operating lease liabilities | -2,385 | -5,700 | -8,326 | -8,604 |
| Accrued interest | 0 | 0 | 21,977 | - |
| Income tax payable | 85,045 | - | - | - |
| Other | - | - | - | -3,304 |
| Other liabilities | -1,008 | -9,280 | 7,540 | - |
| Net cash used in operating activities | -750,349 | -839,451 | -765,268 | -843,393 |
| Available For Sale Securities Debt | 4,795,855 | - | - | - |
| Available For Sale | 1,122,300 | - | - | - |
| Proceeds from sales | 821,367 | - | - | - |
| Purchase of marketable securities | - | 4,061,521 | - | - |
| Held To Maturity Securities | 0 | - | - | - |
| Maturities of marketable securities | - | 1,960,000 | - | - |
| Held To Maturity | 2,185,000 | - | - | - |
| Proceeds from sale of telavant net assets, net | 0 | 110,387 | 5,233,396 | - |
| Proceeds from sale of subsidiary interests | 0 | 260,586 | 47,500 | - |
| Cash decrease upon deconsolidation of subsidiaries | 4,418 | 31,223 | 84,483 | 6,706 |
| Proceeds from sale of investment | - | - | - | 0 |
| Proceeds from sale of myovant top-up shares | - | 0 | 0 | 114,561 |
| Milestone payments | - | 0 | 0 | 140,136 |
| Purchase of property and equipment | 8,209 | 4,599 | 1,382 | 12,690 |
| Other | 2,518 | -79 | -8,592 | -702 |
| Net cash (used in) provided by investing activities | -682,333 | -1,766,291 | 5,203,623 | -44,269 |
| Repurchase of the companys common shares-Parent Company | 318,103 | - | - | - |
| Repurchase of the company's common shares | - | 1,293,232 | - | - |
| Repurchase of the companys common shares-Subsidiaries | 1,400 | - | - | - |
| Proceeds from issuance of the companys common shares, net of issuance costs paid | 0 | 0 | 199,822 | 311,981 |
| Proceeds from business combination and pipe financing | - | - | - | 0 |
| Proceeds from issuance of subsidiary common shares, net of issuance costs paid | - | 112,782 | 238,733 | 67,727 |
| Proceeds from payment of subscription receivable | - | - | - | 0 |
| Proceeds from subsidiary debt financings, net of financing costs paid | - | 0 | 0 | 159,899 |
| Proceeds from issuance of subsidiary common shares, net of issuance costs paid | 193,605 | - | - | - |
| Repayment of debt by subsidiary | 0 | 51,979 | 29,158 | 29,452 |
| Payment of offering costs and loan origination costs | - | 0 | 0 | 2,250 |
| Contribution from minority interest holder to subsidiary | 39,250 | - | - | - |
| Proceeds from exercise of the companys and subsidiary stock options | 268,350 | 49,597 | 54,314 | 2,814 |
| Taxes paid related to net settlement of equity awards | 48,621 | 37,216 | 37,715 | 10,881 |
| Proceeds from issuance of the companys common shares under employee stock purchase plan | 1,155 | 1,028 | 951 | 316 |
| Payments on principal portion of finance lease obligations | 0 | 774 | 1,547 | 692 |
| Payment of subsidiary dividend | 0 | 0 | 6,000 | - |
| Proceeds from exercise of the companys warrants | 0 | 0 | 5 | - |
| Other | - | - | - | 0 |
| Payment for redemptions of the companys warrants | 0 | 0 | 41 | - |
| Net cash provided by (used in) financing activities | 134,236 | -1,219,794 | 419,364 | 499,462 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | - | - | 616 | 6,281 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 3,767 | 747 | - | - |
| Net change in cash, cash equivalents and restricted cash | -1,294,679 | -3,824,789 | 4,858,335 | -381,919 |
| Cash and cash equivalents at beginning of period | - | - | 1,692,115 | 2,074,034 |
| Cash, cash equivalents and restricted cash at beginning of period | 2,725,661 | 6,550,450 | - | - |
| Cash and cash equivalents at end of period | - | - | 6,550,450 | 1,692,115 |
| Cash, cash equivalents and restricted cash at end of period | 1,430,982 | 2,725,661 | - | - |
Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV)